Format

Send to

Choose Destination
Semin Cancer Biol. 2018 Dec;53:156-167. doi: 10.1016/j.semcancer.2018.11.006. Epub 2018 Nov 22.

Therapy resistance mediated by cancer stem cells.

Author information

1
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Innsbruck, Innsbruck, Austria.
2
Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria; EXTRO-Lab, Tyrolean Cancer Research Institute, Innsbruck, Austria.
3
Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
4
Department of Therapeutic Radiology and Oncology, Medical University of Innsbruck, Innsbruck, Austria; EXTRO-Lab, Tyrolean Cancer Research Institute, Innsbruck, Austria. Electronic address: Ira.Skvortsova@i-med.ac.at.

Abstract

Cancer stem cells (CSC) possess abilities generally associated with embryonic or adult stem cells, especially self-renewal and differentiation. The CSC model assumes that this subpopulation of cells sustains malignant growth, which suggests a hierarchical organization of tumors in which CSCs are on top and responsible for the generation of intratumoral heterogeneity. Effective tumor therapy requires the eradication of CSC as they can support regrowth of the tumor resulting in recurrence. However, eradication of CSC is difficult because they frequently are therapy resistant. Therapy resistance is mediated by the acquisition of dormancy, increased DNA repair and drug efflux capacity, decreased apoptosis as well as the interaction between CSC and their supporting microenvironment, the CSC niche. This review highlights the role of CSC in chemo- and radiotherapy resistance as well as possible ways to overcome CSC mediated therapy resistance.

KEYWORDS:

Cancer stem cells; DNA repair; Dormancy; EMT; Stem cell niche

PMID:
30471331
DOI:
10.1016/j.semcancer.2018.11.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center